Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data
06.02.2026 - 21:25:04
The year 2026 is shaping up to be a critical period for Vir Biotechnology, with a series of scheduled clinical data readouts poised to define the company’s trajectory. Investors are keenly awaiting updates on its oncology programs and clarity on its long-term financial runway, with the upcoming Q4 2025 earnings report set to provide a detailed operational snapshot.
The company’s near-term focus is on two key clinical assets. This month, Vir is scheduled to present updated Phase 1 data for VIR-5500 at the ASCO Genitourinary Cancers Symposium. This trial involves patients with late-line, metastatic castration-resistant prostate cancer, with the market looking for insights into the candidate’s safety and Read more...
